One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:Risedronate sodium 2.5-hydrate CAS No.:329003-65-8 Standard:USP, EP Price(USD):Negotiable Company:ZF Polpharma S.A.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: yes
Payment Terms: L/C
Risedronate sodium 2.5-hydrate
Long experience in in-house commercial manufacturing
Extensive portfolio of Bisphosphonates
Technology not generating genotoxic impurities
Status
Commercial
Therapeutic cat.
Musculo-skeletal
Polymorphic form
Form A
CAS No.
329003-65-8
Injectable Form
Injectable
EU DMF readiness
CEP
JAPANESE DMF
KOREAN DMF
CANADIAN DMF
CADIFA
US DMF readiness
Drug description
Risedronate is used to treat osteoporosis caused by menopause, or steroid use. risedronate is for use when you have a high risk of bone fracture due to osteoporosis. Risedronate is also used to treat Paget's disease of bone. Risedronate may also be used for purposes not listed in this medication guide.
Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
Audited Supplier
Pharma Sources Insight January 2025
